NYSE:GENGenesis Healthcare Stock Price, Forecast & News

Genesis Healthcare's stock was trading at $1.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GEN shares have decreased by 10.3% and is now trading at $1.04. View which stocks have been most impacted by Coronavirus.

Genesis Healthcare is scheduled to release its next quarterly earnings announcement on Wednesday, May 27th 2020. View our earnings forecast for Genesis Healthcare.

Genesis Healthcare will be holding an earnings conference call on Wednesday, May 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Genesis Healthcare Inc (NYSE:GEN) released its earnings results on Monday, March, 16th. The company reported ($0.10) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.11) by $0.01. The company earned $1.14 billion during the quarter. Genesis Healthcare had a net margin of 0.32% and a negative return on equity of 1.33%. During the same quarter in the prior year, the business earned ($0.67) EPS. View Genesis Healthcare's earnings history.

News coverage about GEN stock has trended somewhat negative on Sunday, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Genesis Healthcare earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutGenesis Healthcare.

Genesis Healthcare saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,300,000 shares, an increase of 8.0% from the April 30th total of 2,130,000 shares. Based on an average trading volume of 393,000 shares, the short-interest ratio is currently 5.9 days. Currently, 4.2% of the company's stock are sold short. View Genesis Healthcare's Current Options Chain.

Some companies that are related to Genesis Healthcare include Varex Imaging (VREX), Quanterix (QTRX), Relmada Therapeutics (RLMD), G1 Therapeutics (GTHX), Hanger (HNGR), Codexis (CDXS), Osiris Therapeutics (OSIR), Castle Biosciences (CSTL), AVITA MED LTD/S (AVMXY), Orthofix Medical (OFIX), Integral Diagnostics (IDX), Vericel (VCEL), Nextgen Healthcare (NXGN), Morphic (MORF) and Sinovac Biotech (SVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Genesis Healthcare investors own include Flaherty&Crumrine Prfrd Scts Incm Fd (FFC), Vaxart (VXRT), Advanced Micro Devices (AMD), Amarin (AMRN), Anavex Life Sciences (AVXL), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Aduro BioTech (ADRO) and Gilead Sciences (GILD).

Genesis Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "GEN."

Genesis Healthcare's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (2.74%), First Washington CORP (2.18%), Acadian Asset Management LLC (0.99%), State Street Corp (0.79%), Geode Capital Management LLC (0.48%) and Nuveen Asset Management LLC (0.35%). Company insiders that own Genesis Healthcare stock include David A Reis, George V Hager, Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young and Thomas Divittorio. View institutional ownership trends for Genesis Healthcare.

GEN stock was sold by a variety of institutional investors in the last quarter, including First Washington CORP, BlackRock Inc., JPMorgan Chase & Co., UBS Group AG, and Nuveen Asset Management LLC. Company insiders that have sold Genesis Healthcare company stock in the last year include George V Hager, Jr, Joanne Susan Reifsnyder, Michael Scott Sherman, Paul David Bach, Stephen Scott Young, and Thomas Divittorio. View insider buying and selling activity for Genesis Healthcare.

GEN stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, State Street Corp, SG Americas Securities LLC, Connor Clark & Lunn Investment Management Ltd., Wells Fargo & Company MN, and Acadian Asset Management LLC. View insider buying and selling activity for Genesis Healthcare.

Shares of GEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GEN stock can currently be purchased for approximately $1.04.

Genesis Healthcare has a market capitalization of $171.40 million and generates $4.57 billion in revenue each year. The company earns $14.62 million in net income (profit) each year or $0.10 on an earnings per share basis. Genesis Healthcare employs 55,000 workers across the globe.

The official website for Genesis Healthcare is www.genesishcc.com.

Genesis Healthcare's mailing address is 101 EAST STATE STREET, KENNETT SQUARE PA, 19348. The company can be reached via phone at 610-444-6350 or via email at [email protected]